Biocon Stelara Settlement Places Firm Among Earlier US Rivals

Indian Biosimilars Giant Secures Early 2025 Launch Date For Ustekinumab

 
• By Dave Wallace

Biocon Biologics has secured a launch date for its planned US biosimilar to Stelara that puts it ahead of some of the competition.

Jumping Queue Of Arrows
Biocon has jumped ahead of several other biosimilars • Source: Shutterstock

More from Deals

More from Business